Systemic inflammation in COVID-19 patients is a participant effector that magnifies vascular pathology, as it includes the pro-coagulant mediators IL-6 plus IL-6R, which induce the vascular-permeability effector VEGFA. This evidence concerns the gene IL6R and COVID-19.